RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Cervical Cancer Channel

subscribe to Cervical Cancer newsletter
Latest Research : Cancer : Cervical Cancer

   EMAIL   |   PRINT
HPV Vaccination: Predicting Its Effect on Cervical Cancer Rates

Apr 5, 2006 - 9:21:00 PM , Reviewed by: Priya Saxena
The researchers conclude that the most effective strategy for the reduction of cervical cancer in developed countries in which incidence is already low is widespread vaccine coverage (both in terms of the HPV type targeted and the fraction of the population vaccinated), combined with current screening protocols.

 
[RxPG] Each year, nearly 500,000 new cases of cervical cancer are diagnosed around the world, and more than 250,000 women die from the disease. Most of these cases occur in developing countries where there is no routine screening for precancerous lesions. By contrast, in developed countries, national screening programs have greatly reduced the number of women dying from this cancer—between 1955 and 1992 in the US, for example, cervical cancer deaths dropped by 74%.

Infection with a sexually transmitted human papillomavirus (HPV) is a precondition for the development of cervical cancer. Of the 35 HPV types that can infect the genital tract, about half have oncogenic potential—the rest cause benign warts. The immune system clears most HPV infections but persistent infection with HPV type 16 accounts for approximately 55% of cervical cancers. Because of the strong association between cervical cancer and HPV infection, several HPV type-specific vaccines are being developed. Early results suggest that these vaccines can prevent almost 100% of persistent infections with the relevant HPV type, raising the possibility of reducing the incidence of cervical cancer by prophylactic vaccination. But what would the impact of such vaccines be in countries that already have cervical cancer screening programs? To find out, Ruanne Barnabas and colleagues have developed a dynamic transmission model of HPV 16 infection and progression to cervical cancer using epidemiological data from Finland. Their analyses indicate that high coverage of women alone over many decades with a vaccine that provides long-term protection would greatly reduce type-specific cancer incidence, a reduction that would be maximized by combining vaccination with routine screening.

The researchers' model is represented by a flow chart in which susceptible women acquire an HPV infection that, in most cases, is cleared by their immune system. In some women, persistent infection induces precancerous lesions that can progress to invasive cervical cancer, regress spontaneously, or be screened and treated. HPV infection in men is represented by a simpler flow chart—they simply become infected and then develop immunity. The researchers incorporated values for parameters such as sexual activity, screening protocols, and treatment rates obtained from published Finnish studies in their model and calibrated it using historical data on the proportion of the Finnish population with antibodies to HPV 16.

To allow them to model how vaccination will affect the incidence of cervical cancer, Barnabas and colleagues first estimated the transmission probability of HPV in the Finnish population. This probability provides a measure of how easily HPV spreads—if it were 1.0, every sexual partnership a woman had with a man infected with HPV would result in her also becoming infected. The researchers' transmission probability estimate of 0.6 is high, which indicates that universal coverage with a very effective vaccine will be needed to eliminate HPV infection in the population. The researchers put this value (which is subject to great uncertainty) and estimated values for age at sexual debut and the annual number of sexual partners into their model; they also assumed that vaccination takes place before sexual debut, is 100% effective, and gives life-long protection.

The model predicts that vaccinating both men and women will be little better than vaccinating women alone, irrespective of whether vaccine coverage is high or low. Furthermore, although vaccinating 90% of young women before sexual debut could decrease HPV type-specific cervical cancer incidence by 91%, delaying vaccination until after sexual debut could decrease the impact of vaccination. The model also predicts that if 90% of women were vaccinated without screening, there would be 0.6 cases of cervical cancer per 100,000 women per year (compared with seven out of 100,000 with no intervention); vaccination plus screening every five years would reduce this incidence further, by two-thirds. Finally, the researchers investigated how the duration of vaccine-conferred protection might affect invasive cervical cancer rates. The model predicts that—unintuitively—short-lived protection will marginally increase cervical cancer rates compared with no vaccination if, as some people believe, older women are more susceptible to the persistent HPV infections that progress to cervical cancer than are younger women. Booster vaccinations would avoid this potential problem.

The researchers conclude that the most effective strategy for the reduction of cervical cancer in developed countries in which incidence is already low is widespread vaccine coverage (both in terms of the HPV type targeted and the fraction of the population vaccinated), combined with current screening protocols. Whether this recommendation is adopted will depend on how vaccines perform in ongoing phase III trials and on a detailed economic assessment of the options available.



Publication: (2006) HPV Vaccination: Predicting Its Effect on Cervical Cancer Rates. PLoS Med 3(5): e202
On the web: Read Research Article 

Advertise in this space for $10 per month. Contact us today.


Related Cervical Cancer News
New vaccine prevents cervical cancer in teens
Topotecan for Late-Stage Cervical Cancer Approved
New HPV vaccine is 100 percent effective
Vaccine for Cervical Cancer Approved in US - Overview
Quadrivalent Human Papillomavirus (HPV) Recombinant Vaccine Approved by FDA
HPV Vaccination: Predicting Its Effect on Cervical Cancer Rates
HPV testing is more sensitive for screening cervical cancer
Community's income status predicts cervical screening rates
Novel technique to remove "inoperable" cervical spinal tumours
HPV Vaccine Prevented 100 Percent of Cervical Pre-cancers

Subscribe to Cervical Cancer Newsletter

Enter your email address:


 Additional information about the news article
DOI: 10.1371/journal.pmed.0030202

Published: April 4, 2006

Copyright: © 2006 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)